Investors

Press Releases

Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.

Select Year
Search …

Found 316 Results

FDA Confirms Acceptability of Palatin’s Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

August 28, 2024

First Patient Dosed in Phase 2 Clinical Study of Palatin’s Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

August 22, 2024

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

June 21, 2024

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

June 20, 2024

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

June 12, 2024

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

May 15, 2024

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

May 9, 2024

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

May 2, 2024

Palatin to Host Virtual KOL Event “Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance” on May 8, 2024

April 30, 2024

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

April 8, 2024

Newer

Page 2 of 32

Older